Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal
Year of publication: |
2012
|
---|---|
Authors: | Boyers, Dwayne ; Jia, Xueli ; Jenkinson, David ; Mowatt, Graham |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 30.2012, 6, p. 483-495
|
Publisher: |
Springer Healthcare | Adis |
Subject: | Anti-D-Rh0-immunoglobulin | Cost-effectiveness | Cost-utility | Decision-making | Eltrombopag | Idiopathic-thrombocytopenic-purpura | Immune-thrombocytopenic-purpura | Rituximab | Romiplostim |
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
-
Cost Effectiveness of Rituximab for Non-Hodgkin's Lymphoma: A Systematic Review
Auweiler, Philipp W.P., (2012)
-
Quality-of-Life Assessment in Rheumatoid Arthritis
Russell, Anthony S., (2008)
-
Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal
Whyte, Sophie, (2012)
- More ...
-
Boyers, Dwayne, (2013)
-
Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura
Boyers, Dwayne, (2012)
-
Kilonzo, Mary, (2013)
- More ...